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Heavy menstrual bleeding, or menorrhagia, is subjectively deﬁned as a “complaint of a large amount of
bleeding during menstrual cycles that occurs over several consecutive cycles” and is objectively deﬁned
as menstrual blood loss of more than 80 mL per cycle that is associated with an anemia status (deﬁned as
a hemoglobin level of <10 g/dL). During their reproductive age, more than 30% of women will complain
of or experience a heavy amount of bleeding, which leads to a debilitating health outcome, including
signiﬁcantly reduced health-related quality of life, and a considerable economic burden on the health
care system. Although surgical treatment might be the most important deﬁnite treatment, especially
hysterectomy for those women who have ﬁnished bearing children, the uterus is still regarded as the
regulator and controller of important physiological functions, a sexual organ, a source of energy and
vitality, and a maintainer of youth and attractiveness. This has resulted in a modern trend in which
women may reconsider the possibility of organ preservation. For women who wish to retain the uterus,
medical treatment may be one of the best alternatives. In this review, recent trends in the management
of women with heavy menstrual bleeding are discussed.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Heavy menstrual bleeding (HMB), deﬁned as a blood loss of
more than 80mL per cycle and often accompaniedwith anemia, is a
major reason for gynecologic consultations around the world.
Womenwith HMB experience a diminished quality of life and a loss
of work productivity, and face high expenses for medical services
[1]. Various terms have been used to describe HMB, including
menometrorrhagia, metrorrhagia, menorrhagia, and polymenor-
rhea. The confusing and inconsistently applied nomenclature and
the lack of standardized methods for investigation and categori-
zation of the various potential etiologies make it difﬁcult toepartment of Obstetrics and
ational Yang-Ming University
pei, Taiwan.
g@ym.edu.tw (P.-H. Wang).
icle.
bstetrics & Gynecology. Publishedcompare studies performed by different investigators or research
groups. Therefore, a universally accepted system of nomenclature
and classiﬁcation seems to be a necessary step in the evolution of
collaborative research and evidence-based application of results to
clinical practice [1]. In addition, an accurate diagnosis based on a
universally accepted system of nomenclature and classiﬁcation
might offer a better understanding of the pathophysiology of HMB,
which would help physicians make better decisions regarding the
management of women with this condition. After an effective
treatment, good control of the patient's symptoms and signs will
improve her quality of life [2e4].
To clearly demonstrate HMB, the Menstrual Disorders Working
Group of the International Federation of Gynecology and Obstetrics
(FIGO) has proposed abandoning the use of one common term,
“dysfunctional uterine bleeding” [5]. There are nine main cate-
gories, arranged according to the acronym PALMeCOEIN (polyp,
adenomyosis, leiomyomas, malignancy, hyperplasiaecoagulopathy,by Elsevier Taiwan LLC. All rights reserved.
Figure 1. PALMeCOEIN (polyp, adenomyosis, leiomyomas, malignancy, hyperplasia- coagulopathy, ovulatory dysfunction, endometrial disorders, iatrogenic causes and not-yet-
classiﬁed entities) system for heavy menstrual bleeding.
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not-yet-classiﬁed entities) (Figure 1). The PALM categories include
polyp, adenomyosis, leiomyomas, and malignancy and hyperplasia
[5]. In general, the components of PALM are structural etiologies,
which can be measured visually because they can be evaluated by
clinical examination, imaging techniques, or histopathology [6]. It is
difﬁcult to deﬁne a COEIN status by imaging or histopathology,
since COEIN is related to nonstructural entities [6], including coa-
gulopathy, ovulatory dysfunction [7], endometrial disorders by
exclusion of other identiﬁable abnormalities in women of repro-
ductive age; , iatrogenic causes, such as insertion of an intrauterine
system [8] or medicine directly impacting the endometrium [9],
interfering with blood coagulation mechanisms (warfarin, heparin,
and low-molecular-weight heparin) [10], and inﬂuencing the sys-
temic control of ovulation, and not-yet-classiﬁed entities, including
chronic endometritis [11], arteriovenous malformation [12], myo-
metrial hypertrophy, and possible future entities.
The primary classiﬁcation system reﬂects only the presence (1)
or absence (0) [5,6], and cannot totally show the severity of dis-
eases. Therefore, a secondary classiﬁcation system may be needed
in some subgroups. For example, leiomyomas involving the endo-
metrial cavity [submucosal (SM)] need to be distinguished from
others (O) because SM lesions are most likely to contribute to the
genesis of HMB [5]. Tertiary subclassiﬁcation of leiomyoma types
requires the clinicians to determine the relationship between the
leiomyomas and the endometrium, myometrium, and serosa [13].
SM types are 0 (pedunculated intracavitary), 1 (<50% intramural),
and 2 (50% intramural), and the others are 3 (contracts endo-
metrium, 100% intramural), 4 (intramural), 5 (subserosal 50%
intramural), 6 (subserosal <50% intramural), 7 (subserosal pedun-
culated), and 8 (includes cervical or parasitic and other lesions not
related to the myometrium) [14].
The PALMeCOEIN system not only allows clinicians and re-
searchers to identify and classify women with HMB in a systematic
manner, but also provides reliable information for researchpurposes and for epidemiological and prevalence studies in
different settings [15]. This classiﬁcation is useful for patient-
tailored therapy, especially for differential stages of women's
reproductive years and for different patterns of HMB [15]. It is
important to keep inmind that many of these causes of HMB can be
asymptomatic, and that HMB itself might be the ﬁrst symptom or
the only symptom presented by patients [16,17].
Strategy to evaluate women with HMB
Measuring menstrual blood loss accurately is impractical
because of the complexity of the techniques [15]. Therefore, HMB
could be deﬁned as “excess menstrual blood loss interfering with
women's physical, emotional, social and material quality of life.”
HMB can occur alone or in combination with other symptoms.
Normal limits of menstruation in women include: (1) a menstrual
period frequency ranging from 24 days to 38 days; (2) duration of
blood ﬂow ranging from 4 days to 8 days; and (3) the volume of
monthly blood ﬂow ranging from 5 mL to 80 mL [6]. The cause of
HMB can be clearly separated from structural and nonstructural
problems. Therefore, all women with HMB should be treated in as
diligent and comprehensive a fashion as is practicable, given the
clinical situation and the available resources [5]. That is to say, we
need to establish necessary parameters to achieve an accurate
diagnosis and treatment for women with HMB (Figure 2).
Clinicians should perform a careful evaluation of a woman of
reproductive age with HMB, to ensure that the bleeding is not
related to an undiagnosed pregnancy and is emanating from the
cervical os, rather than from another location [5]. The bleeding
should be conﬁrmed, in the absence of any other identiﬁable source
[18]. In addition, a structured history, including the age of the
woman, regularity of menstrual cycles and accompanying
menstruation problems (for example, dysmenorrhea), beginning
and frequency of HMB, symptoms or signs of a tendency to bleed,
bruises, epistaxis, and a family history, should be taken and
Figure 2. Algorithm for evaluation of women with heavy menstrual bleeding. HMB ¼ heavy menstrual bleeding.
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if coagulopathy problems, which occur in approximately 13% of
women with HMB, cannot be totally excluded [14].
Basic technologies for investigation of different causes include
transvaginal ultrasound (and/or transabdominal ultrasound), tissue
biopsy, histology, and diagnostic hysteroscopy. Transvaginal ultra-
soundmight be one of the most convenient, economical, and useful
image modalities to evaluate women with HMB. Adequate quality
to display myometrial and endometrial features clearly is impor-
tant for ideal imaging by transvaginal ultrasound. Endometrial
sampling should be considered in women over a certain age, usu-
ally 45 years, and with a family history of genetic disorders, such as
hereditary nonpolyposis colorectal cancer syndrome [19], since the
possibility of endometrial cancer should be excluded [20], even
though ovulation disorders are also frequently noted in women
during the menopausal transition. To detect adenomyosis, its
variance (adenomyoma), or submucosal myoma more accurately,
magnetic resonance imaging may be needed, although it is not
practical at the present time [21e23].
Medical treatment
In women with deﬁnite causes of HMB, therapeutic choices
should be based on the PALMeCOEIN system. For polyps, surgical
removal is highly recommended, especially the use of minimally
invasive procedures, such as hysteroscopy [24,25]. For certain types
of leiomyomas, for example, SM leiomyomas, surgical removal is
frequently required, although medical treatment can work in some
cases. Hysteroscopic resection, by either a one- or two-step pro-
cedure, or after preoperative hormonal therapy, including
gonadotropin-releasing hormone agonist (GnRH agonist) and/or
ulipristal acetate (one of the selective progesterone receptor
modulatorsdSPRMs) [26e28], has been well accepted as the
treatment of choice [29,30]. Endometrial lesions should be
managed based on the pathological ﬁndings. Precancer lesions,
including endometrial hyperplasia with and/or without atypia, orsome early-stage and well-differentiated (Grade 1) endometrioid-
type endometrial cancers, could be managed conservatively.
These conservative treatments include high-dose progestin and/or
other hormonal therapies [20,31]. However, conservative medical
treatment for womenwith endometrial precancer or endometrioid
cancer is not totally free of risk. The following criteria or consid-
erations should be carefully evaluated: (1) the potential oncologic
risk should be assessed, since the persistent, progressive rate of
cancer is 15e25%; (2) a good candidate for conservative treatment
should be younger than 40 years, should have a need to give birth,
and have an ability to give birth; (3) the disease should be limited to
2009 FIGO IA and this diagnosis should be conﬁrmed by gyneco-
logicepathologic experts; (4) the treated women should have good
compliance and not have any contraindication to high-dose pro-
gestins; (5) thewomen should be informed that the initial response
rate of the drugs ranges from 50% to 70%; (6) these conservative
treatments often include hormones, such as medroxyprogesterone,
megestrol, and levonorgestrel-releasing intrauterine system (LNG-
IUS) ± GnRH agonist; (7) the hormone dosage should be adminis-
tered adequately, and the frequently used medication includes
200e800mgmedroxyprogesterone and 80e320 mgmegestrol; (8)
the women should have excellent compliance and adequate sur-
veillance, which should occur every 2e6 months; (9) after con-
servative medical treatment, these women have only a 30e40%
chance of a successful reproductive outcome; and (10) these pa-
tients need counseling by well-trained team workers [31,32].
Coagulation problems and endocrinopathy could be managed
based on their deﬁnite causes. Iatrogenic causes could be managed
by removal of the iatrogenic factors andmodiﬁcation of dosage use.
Other important causes of HMB include not-yet-classiﬁed entities,
such as chronic endometritis, especially chlamydial infection [33],
arteriovenous malformation, myometrial hypertrophy, and
possible future entities. Some of these not-yet-classiﬁed entities
could be managed by antibiotics and embolization [34].
Women with uterine leiomyoma and/or adenomyosis can be
managed with medical treatment. Our previous studies reviewed
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gestrinone, danazol, progestins, oral pills, LNG-IUS, and GnRH
agonist are discussed.
Among these medications, SPRMs, including ulipristal acetate,
mifepristone, asoprisnil, lonaprisan, telapristone acetate, PRA-910,
ZK 136799, and onapristone, inhibit endometrial proliferation or
suppress leiomyoma and/or adenomyotic lesions, resulting in in-
hibition of prostaglandin production and shrinkage of leiomyoma
and/or adenomyotic lesions, and endometrial atrophy, suggesting
that these beneﬁcial effects of SPRMs treatment may reﬂect
changes in the endometrial morphology and/or the absence of
bleeding [39]. A recent head-to-head comparison study showed
that ulipristal acetate (one of the SPRMs) was superior to placebo
and not inferior to leuprolide acetate (one of the GnRH agonists) for
the control of HMB. More than 90% of women treated with uli-
pristal acetate had a clinically signiﬁcant decrease in bleeding, and
approximately three-fourths became amenorrheic [39]. The SPRMs
might be promising agents in the management of uterine ﬁbroid-
related HMB; however, a potential safety issue for the endome-
trium is still concerned [40].
Evidence regarding the use of oral pills as treatment for women
with symptomatic ﬁbroids is very scarce and of low quality;
therefore, a recent systematic review questioned the real efﬁcacy of
oral pills in women with symptomatic uterine ﬁbroids [41].
LNG-IUS has been found to be more effective than oral medi-
cation as a treatment for HMB [42,43]. In addition, LNG-IUS is
associatedwith a greater reduction in HMB and improved quality of
life, and appears to be more acceptable in long-term treatment, but
is associated with more minor adverse effects compared to oral
therapy [41]. Therefore, some physicians have recommended that
LNG-IUS should be used as a ﬁrst-line medical therapy for HMB in
women not seeking pregnancy [42].
The 2011 report of the Agency for Healthcare Research and
Quality on comparative management of uterine ﬁbroids showed
that, despite the prevalence and possible complications of uterine
ﬁbroids, few published studies examining the effectiveness of
treatment strategies exist [44]. Few therapies are approved by the
Food and Drug Administration for ﬁbroids; leuprolide acetate, a
GnRH agonist approved in 1995 for preoperative treatment of ﬁ-
broids, is a gold-standard drug in the management of women with
uterine ﬁbroid- and/or adenomyosis-related symptoms or signs.
However, leuprolide acetate, with much more profound suppres-
sion of estradiol levels, signiﬁcantly more hot ﬂashes, and more
substantial effects on markers of bone turnover, had a relatively
poor side-effect proﬁle in women during their reproductive age.Table 1
Summary of the useful medications for women with heavy menstrual bleeding.
Drugs Cost a Opinion and effects compared with placebo
Antiﬁbrinolytics
(tranexamix acid)
2.5 Well tolerated, fewer side effects, a deﬁnite t
NSAIDs 1e2 GI and renal effects, allergy, a deﬁnite therap
Progestins 10e15 Irregular bleeding, nausea/vomiting, mood sw
(87% reduction)
Gestrinone 80 Seborrhea, hypertrichosis, increased body we
cholesterol lipoprotein distribution, a deﬁnit
Danazol 40e100 Seborrhea, hypertrichosis, increased body we
cholesterol lipoprotein distribution (50e70%
OC 10e20 Irregular bleeding, hypercoagulation status, n
LNG-IUS 3e4 Irregular bleeding, abdominal pain, a deﬁnite
GnRH-a 120e200 Frequent and intolerable hypoestrogenic side
negative impact on bone health, and also a p
(reduction of >95%)
GI¼ gastrointestinal; GnRH-a¼ gonadotropin-releasing hormone agonist; LNG-IUS¼ levo
drugs; OC ¼ oral contraceptives or oral pills.
a Cost: US dollars per cycle.Therefore, the add-back therapy of GnRH administration is often
suggested.
Inwomenwithout deﬁnite organic lesions, such as those related
to endometrial, uterine, or endocrine and hematologically
abnormal causes, HMB remains poorly understood and poses a
major challenge to developing novel, efﬁcient therapies for HMB
[15]. The ultimate goal of any form of treatment is to reduce the
amount of menstrual blood. Medical treatment has always been
considered the ﬁrst-line treatment for women with HMB, as a
means of achieving the goal of uterine preservation [45,46]. Con-
servative uterine-sparing surgery or hysterectomy tends to follow
failed or ineffective medical treatment.
Matteson et al [1] conducted a systematic review that included
26 published articles, and found that a signiﬁcant reduction of
blood loss in women with HMB presumed secondary to endome-
trial dysfunction was achieved with a 71e95% reduction in the use
of LNG-IUS, a 35e70% reduction in the use of combined oral pills, an
87% reduction in the use of an extended cycle of oral progestins
(>21 days), a 26e54% reduction in the use of antiﬁbrinolytics
(tranexamic acid), and a 10e52% reduction in the use of nonste-
roidal anti-inﬂammatory drugs (NSAIDs) [1]. However, luteal-
phase progestins should be used only in special cases, since
nearly all the abovementioned therapeutic strategies, including
LNG-IUS (a reduction of 71% comparedwith 22%, p < 0.001), NSAIDs
(a reduction of 67% compared with 52%, in a small sample-size
comparison, n ¼ 32), and antiﬁbrinolytics (a reduction of 45%
compared with 20%, p < 0.001), were all superior to luteal-phase
progestin treatment, with a reduction of 20e67% [1]. In addition,
antiﬁbrinolytics were superior to NSAIDs (a reduction of 54%
compared with 10%, p < 0.001) for reduction of HMB. LNG-IUS was
superior to combined oral pills (a reduction of 83% compared with
68%, p¼ 0.002) and NSAIDs (a reduction of 95% comparedwith 23%,
p < 0.001) [1].
The cost of medications can be referenced from Table 1. Anti-
ﬁbrinolytics, such as 250-mg tranexamic acid, cost US$0.1/tab, are
prescribed as two tabs three times per day and are often used to
cover the whole menstrual period. NSAIDs, such as 200 mg mefe-
namic acid or naproxen, are US$0.1e1/tab, often prescribed as one
tab twice or three times per day, and often used during attacks of
HMB. Medroxyprogesterone (5 mg) is US$0.1/tab; however, it often
requires 20e40 mg/day. In addition, extended use is preferred;
suggesting that use for more than 14 days or continuous use
without more than 7 missed days might have a good therapeutic
effect. The monthly expense of oral pills is US$10e30. LNG-IUS
costs US$100e200 per set; however, the effectiveness isherapeutic value (26e54% reduction)
eutic value (10e52% reduction)
ings, hot ﬂush, increased bodyweight, a deﬁnite therapeutic value in extended use
ight, the risk of metabolic syndrome such as unfavorable effects on serum
e therapeutic value (50e70% reduction)
ight, and the risk of metabolic syndrome such as unfavorable effects on serum
reduction)
ausea/vomiting, headache, a deﬁnite therapeutic value (35e70% reduction)
therapeutic value (71e95% reduction)
effects, including vasomotor syndrome, genital atrophy, mood instability, a
ossible bad inﬂuence on cardiovascular health; a deﬁnite therapeutic value
norgestrel-releasing intrauterine system; NSAIDs¼ nonsteroidal anti-inﬂammatory
Y.-J. Chen et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 483e488 487maintained for 5 years. The ﬁnal medication is GnRH agonist, which
is the most expensive (US$150/month), and many women with
HMB taking GnRH agonist might be compromised by severe
menopause-related problems, as shown above. Therefore, GnRH
agonist is seldom considered as the ﬁrst-line treatment in the
management of women with HMB; it is often used for special in-
dications, such as long-term suppression of in vitro fertilization and
embryo transfer, and pre- and postoperative adjuvant therapy.
Comments
Based on the above evidence, the Taiwan Society of Gynecology
Systematic Review Group has developed clinical practice sugges-
tions for medical treatment of HMB, which include the following:
(1) clinicians should use the FIGO PALMeCOEIN system to perform
a structured history review and physical examination to detect
organic and/or nonorganic lesions that can be reversed by deﬁnite
treatment; (2) no deﬁnite cause-related HMB can be managed us-
ing a step-by-step strategy, based on cost effectiveness and pa-
tients' preference (low cost, more convenience, few adverse events,
and high compliance); (3) in the situation of B status, two agents
could be used as a choice, including that LNG-IUS is preferred for
women with HMB needing contraception; the use of two tabs of
tranexamic acid three times per day is often preferred to cover the
whole menstrual period for any womanwithout an organic-related
HMB; and (4) patient-tailored therapy should always be
considered.
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